Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies
Taletrectinib (AB-106/DS-6051b) is an oral, potent selective ROS1 and pan-NTRK tyrosine kinase inhibitor (TKI). Preclinically, taletrectinib has activity against ROS1 G2032R solvent-front mutation. Patients with ROS1+ NSCLC enrolled into two phase 1 studies conducted in United States (U101, NCT02279...
Saved in:
Published in | JTO clinical and research reports Vol. 2; no. 1; p. 100108 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.01.2021
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!